The American Journal of Managed Care

Variability of Frequency Dosing for Anti-VEGF Agents in the Treatment of Wet AMD

Dr Coney discusses the variability of frequency dosing with anti-VEGF therapy in patients with wet AMD and DME, and Dr Sheth expands on Ang-2 and its contribution to the development of vascular ...
Healio

Observe-and-plan regimen efficient for anti-VEGF treatment of wet AMD

Please provide your email address to receive an email when new articles are posted on . The average number of annual injections decreased from 8.7 in year 1 to 4.7 in year 7. The regimen could reduce ...
The American Journal of Managed Care

Contributor: AI-Based Remote Monitoring for Age-Related Macular Degeneration: Promise, Progress, and Pitfalls

Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision impairment in adults, affecting ...
Healio

Low adherence to anti-VEGF injections results in declining mean visual acuity

Please provide your email address to receive an email when new articles are posted on . Visual acuity increased by 3 letters on average at year 1. By year 6, annual decreases led to a net loss of 4.6 ...
Ophthalmology Times

FDA expands faricimab label to include treatment of macular edema secondary to retinal vein occlusion beyond 6 months

The FDA’s decision to extend the labeled duration of faricimab use in RVO beyond 6 months primarily reflects accumulated ...
GEN

Wet AMD Treatments Could Work Better If Both VEGF and ANGPTL4 Are Targeted

Researchers led by a team at the Wilmer Eye Institute, Johns Hopkins Medicine, have discovered why vision in some patients with neovascular (nv) or “wet” age-related macular degeneration (nvAMD, or ...
Forbes

A Clear Vision: Anti-VEGF Treatment For Neovascular “Wet” Age-Related Macular Degeneration

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...